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Chronic neurohormonal and mechanical stresses are central fea-
tures of heart disease. Increasing evidence supports a role for
the transient receptor potential canonical channels TRPC3 and
TRPC6 in this pathophysiology. Channel expression for both is nor-
mally very low but is increased by cardiac disease, and genetic
gain- or loss-of-function studies support contributions to hypertro-
phy and dysfunction. Selective small-molecule inhibitors remain
scarce, and none target both channels, which may be useful given
the high homology among them and evidence of redundant sig-
naling. Here we tested selective TRPC3/6 antagonists (GSK2332255B
and GSK2833503A; IC50, 3–21 nM against TRPC3 and TRPC6) and
found dose-dependent blockade of cell hypertrophy signaling trig-
gered by angiotensin II or endothelin-1 in HEK293T cells as well as in
neonatal and adult cardiac myocytes. In vivo efficacy in mice and
rats was greatly limited by rapid metabolism and high protein bind-
ing, although antifibrotic effects with pressure overload were ob-
served. Intriguingly, although gene deletion of TRPC3 or TRPC6
alone did not protect against hypertrophy or dysfunction from
pressure overload, combined deletion was protective, support-
ing the value of dual inhibition. Further development of this
pharmaceutical class may yield a useful therapeutic agent for
heart disease management.
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Cardiac adaptation to loading stress involves a complex pro-cess of chamber remodeling and myocyte molecular mod-
ifications. In response to increased pathological stress, myocytes
enlarge and increase protein synthesis, coupled with excessive
activation of multiple signaling cascades. Previous studies have
revealed that Gαq-coupled receptor signaling plays a central role
in this pathophysiologic process and in turn has been linked to
augmented intracellular calcium signaling (1). For example,
myocyte stimulation by agonists such as angiotensin II (Ang II)
or endothelin-1 (ET-1) or by mechanical stress accompanying
sustained hypertension leads to activation of the Ca2+-calmod-
ulin–dependent phosphatase calcineurin (Cn), which dephos-
phorylates the transcriptional regulator nuclear factor of activated
T cells (NFAT) (2). This results in nuclear NFAT translocation
where it coordinates expression of maladaptive hypertrophic genes.
The source of the triggering Ca2+ that leads to Cn/NFAT
activation has been the subject of debate, but recent work sug-
gests that members of the transient receptor potential canonical
channel superfamily, TRPC3 and TRPC6, likely play a central
role (3–5). TRPC3 and TRPC6 are highly homologous non–
voltage-gated and nonselective cation channels (6, 7). They are
normally expressed at very low levels in myocytes, but levels are
increased in cardiac disease, such as pressure overload (3, 4, 8,
9). TRPC6 is essential for the transformation of fibroblasts to
myofibroblasts and corresponding scar formation (10). Both
species can be directly activated by diacylglycerol coupled to Gαq
signaling, and TRPC6 is also stimulated by mechanical stretching
and oxidative stress (7, 11, 12). Cardiac myocyte-targeted over-
expression of either protein stimulates chamber hypertrophy and
dysfunction coupled to Cn/NFAT activation in a feed-forward
manner, because both channel genes also contain NFAT con-
sensus sequences in their promoters (3, 4). To date, genetic loss-
of-function studies have relied almost entirely on myocyte-targeted
expression of dominant negative proteins (8) which suppresses
hormone-stimulated or pressure-overload induced hypertrophy;
however, because the channels can form heterotetramers (13),
this approach may afford a poison peptide effect, in which a mu-
tated channel protein interacts with other subtypes. If so, then this
effect should differ from a pure gene deletion model, although this
has not been reported to date.
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Studies using small-molecule inhibitors to examine potential
benefits of TRPC3 and particularly TRPC6 blockade on heart
disease have been stymied by a lack of potent selective antagonists.
Inhibitors such as SKF-96365, 2-aminoethoxydiphenyl borate (14),
and spider venom GsMTx-4 (15) are nonselective. Pyr3 (ethyl-1-(4-
(2,3,3-trichloro-acryl- amide)phenyl)-5-(trifluoromethyl)-1H-
pyrazole-4-carboxylate) has been identified as a selective TRPC3
antagonist (16, 17), although members of the 5-(trifluoro-methyl)-
1H-pyrazole family to which it belongs block Ca2+ release-activated
calcium (CRAC) channels, such as Orai channels (18, 19).
Washburn et al. (20) recently identified aniline-thiazole
pharmacophore-based blockers of both TRPC3 and TRPC6 that
confer nanomolar potency and selectivity. The physiological effects
of these compounds have not been studied, however. Here we
examined the modulation of hypertrophic stimulation in cardiac
myocytes and selectivity for TRPC3 and TRPC6. We studied the
differential impact of single versus combined TRPC3/TRPC6
suppression using gene deletion models. Our findings support
the utility of selective TRPC3/6 antagonism in blocking cardio-
myocyte hypertrophic signaling, and the benefits of targeting
both TRPC species in this setting.
Results
Pharmacological Comparison of TRPC3/6 Dual Antagonists (GSK255B
and GSK503A) with Pyr3. The two compounds used in this study,
GSK2332255B (GSK255B) and GSK2833503A (GSK503A), are
structurally similar, potent, and selective inhibitors of TRPC3/6
with ≥100-fold selectivity over other calcium-permeable chan-
nels (e.g., 104-fold higher IC50 for Cav1.2) (20). They display up
to 100-fold greater potency for TRPC3 compared with Pyr3
(Table 1), and, unlike Pyr3, also inhibit TRPC6. Consistent
with previous reports (19), we also found that Pyr3 blocks store-
operated calcium entry (SOCE) using Jurkat cells, which have high
levels of CRAC, at similar potency as it inhibits TRPC3. The same
assay showed no activity against SOCE with GSK255B (Table 1).
Effect of Dual TRPC3/6 Blockade in Cultured HEK293T Cells. We first
tested the efficacy of TRPC3/6 blockade in a heterologous cell
system, using HEK293T cells transfected with TRPC3, TRPC6,
or empty vector, along with the angiotensin type-1 receptor and
an NFAT-luciferase reporter. We then stimulated the cells with
Ang II with or without GSK255B. HEK293T cells normally ex-
press very low levels of TRPC3 and no TRPC6. Consistent with
this, cells administered empty vector (pcDNA) and stimulated
with Ang II (10 nM) exhibited NFAT activation that was un-
altered by GSK255B or its inactive control (GSK383A) (Fig. 1
A and B). Cells overexpressing (>50-fold) either channel had in-
creased basal NFAT activation that was further amplified by Ang II.
This response was suppressed in a dose-dependent manner by
GSK255B, but not by inactive control (Fig. 1 A and B).
To test whether GSK255B suppressed non–voltage-dependent
sarcolemmal Ca2+ influx, we loaded nonelectrically stimulated
neonatal myocytes with the Ca2+ sensor Fura-2/AM superfused
with 0 mM Ca2+ and 1 μM thapsigargin, the latter to eliminate
sarcoplasmic reticular Ca2+ sources. We then exposed the myo-
cytes to vehicle or to 20 μM phenylephrine (PE), followed by a
switch to 2 mM extracellular Ca2+ (Fig. 1C). This protocol elicited
an increase in intracellular Ca2+ that was further augmented by
PE. The stimulated response was fully prevented by coexposure
to GSK255B.
TRPC6 contains two residues in the N terminus, T70 and S322,
that when phosphorylated by protein kinase G (PKG) potently
suppress channel conductance and corresponding NFAT acti-
vation (9, 21). Thus, we tested whether the TRPC3/6 antagonists
were redundant or additive to this potent posttranslational reg-
ulation. HEK293T cells were transfected with either WT-TRPC6
or a phosphomimetic mutant form (TRPC6-SETE) in which
both PKG-targeted residues were changed to glutamate. As
shown in Fig. 1D, Ang II-stimulated NFAT-luciferase activity in
cells expressing WT-TRPC6 was double that in cells expressing
Table 1. Potency of TRPC3/TRPC6 antagonists compared with
Pyr3
Compound
rTRPC6,
IC50, μM
rTRPC3,
IC50, μM
CRAC,
IC50, μM
Pyr3 (SB-360475) >10 0.47 0.8
GSK2332255B 0.004 0.005 >15
GSK2833503A 0.003 0.021 Not determined
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Fig. 1. Efficacy of TRPC3/6 inhibitor GSK255B on hormone-induced hyper-
trophic signaling in cells. NFAT activation by Ang II is blocked in a dose
dependent manner by GSK255B (0.01, 0.1, and 1 μM) in HEK293T cells
overexpressing TRPC3 (A) or TRPC6 (B). Cells without channel up-regulation
show less Ang II-stimulated NFAT, and no response to the inhibitors, sup-
porting selectivity. An inactive control compound (GSK383A) is also tested at
0.1 μM concentration, and shows no impact. P values shown are for one-way
ANOVA or KW test; symbols denote results of unpaired or post hoc multiple-
comparison tests: #P < 0.05 vs. inactive control; *P < 0.05 and †P < 0.005 vs.
vehicle control and Ang II + pcDNA; §P < 0.005 vs. Ang II + TRPC3 (or TRPC6)
and P < 0.005 vs. vehicle + pcDNA. (C) GSK255B (10 μM) blocks calcium entry
stimulated by PE (20 μM) in rat neonatal cardiac myocytes. TG, thapsigargin
(1 μM). (D) GSK255B blocks NFAT activation by Ang II in HEK293T cells
expressing a mutant TRPC6 channel with T70 and S322 mutated to glutamic
acid (SETE). Data were analyzed by one-way ANOVA or the Kruskal–Wallis
test in the Ang II treatment group for all three TRPC6 channel types. Post hoc
testing: *P < 0.01 vs. non–Ang II-stimulated control for pcDNA, TRPC6-WT, or
TRPC6-SETE transfected cells; #P < 0.005 vs. corresponding response (with or
without Ang II) for pcDNA or TRPC6-SETE transfected cells; †P < 0.05 vs.
other groups in one-way ANOVA (horizontal line identifies groups). §n = 3
for this group.
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TRPC6-SETE; however, this expression was still further suppressed
by GSK255B but not the negative control compound, GSK383A.
Effect of Dual TRPC3/6 Inhibition in Cultured Cardiomyocytes. We
next tested whether the TRPC3/6 antagonists suppress NFAT
activation in both neonatal rat and adult mouse cardiac myocytes.
For these and subsequent studies, we used GSK503A, which is
similar to GSK255B but considered to have potentially better in
vivo pharmacodynamics. Neonatal cardiomyocytes were trans-
fected with an adenovirus encoding a luciferase-coupled reporter
for regulator of Cn (Rcan-1) serving as a readout for Cn/NFAT
activation. Cells stimulated with 0.1 μM ET-1 exhibited a three-
fold increase in Rcan-1 that was suppressed by GSK503A in
a dose-dependent manner, with complete inhibition at 5–10 μM.
Incubation with the corresponding negative control compound
(GSK678A) did not suppress Rcan-1 luciferase activity (Fig. 2A).
The same experiment performed with GSK255B yielded nearly
identical results (Fig. S1).
Voltage-gated calcium entry is associated with hypertrophic
signaling. Because the effective dose in myocytes exceeded that
previously tested against Cav1.2 (20), we performed patch-clamp
analysis in adult mouse myocytes using 10 μM GSK503A. As
shown in Fig. 2B, even this high dose had no effect on the L-type
calcium channel (LTCC) current-voltage (I-V) dependence.
For evaluation of the effect of GSK503A in adult myocytes,
hearts from C57BL/6J mice were first subjected to pressure over-
load (i.e., aortic constriction) to augment basal channel expression
(9). Myocytes were then isolated and were subjected to 24-h
stimulation with 0.1 μM ET-1 with or without 10 μM GSK503A.
Fetal gene markers of pathological hypertrophy (Nppa and
Nppb), as well as Rcan1, Trpc6, and Trpc1, all increased with ET-
1 stimulation (Fig. 2C). The increase in TRPC channel expres-
sion is consistent with a feed-forward activation coupled to Ca2+-
stimulated NFAT activity (3, 22). Coincubation with GSK503A
blunted these changes. When the same experiment was per-
formed in cells genetically lacking both TRPC3/6, the re-
sponse was attenuated compared with WT cells and was
unchanged by the addition of GSK503A. Trpc1 expression also
increased with ET-1 in WT cells, and this response was blunted
by GSK503A as well. Both the rise and drug-induced decline in
Trpc1 expression were not observed in double KO (dKO) cells
exposed to ET-1, indicating that this is an indirect effect of the
suppression of TRPC3/6 rather than an off-target influence
of GSK503A.
TRPC3/6 Combined Mice, But Not Single-Channel KO Mice, Are Protected
Against Pressure Overload-Induced Pathological Remodeling. The li-
brary screen for TRPC3 or TRPC6 antagonists identified com-
pounds generally sensitive to both (20). Selective targeting
previously has been achieved either by dominant negative ex-
pression (8) or with Pyr3, which inhibits TRPC3 (16), both of
which produce antihypertrophic effects. This leaves open the
question of whether similar efficacy occurs when a single species
is genetically deleted. To test this, we subjected mice lacking
TRPC3, TRPC6, or both to 3 wk of pressure overload by trans-
verse aortic constriction (TAC). Selective gene deletion is shown
in Fig. S2. Resting left ventricular (LV) mass and fractional
shortening were similar between each KO group and its re-
spective littermate controls (Fig. 3 A–C). The absolute response
to TAC in each control group varied slightly among genotypes
(P = 0.03, one-way ANOVA), likely reflecting differences in
C57BL/6J/sv129 background. In TRPC3−/− and TRPC6−/− mice,
TAC induced similar hypertrophy and reduced fractional short-
ening as observed in the TAC control mice. The slightly worse-
appearing function in TRPC3−/− (nonsignificant) may be related
in part to persistent TRPC6 expression (Fig. S2). In contrast,
mice lacking both genes displayed a blunted response to TAC
(Fig. 3C). Whereas the dKO mice displayed normal fractional
shortening at 3 wk, this declined after 6–7 wk to levels midway
between those of sham and TAC controls, matching levels of
suppressed hypertrophy (Fig. S3).
The disparate hypertrophic responses in the three models
were further confirmed by postmortem analysis of heart weight/
tibia length (Fig. 4A) and myocyte cross-sectional area (Fig. 4B
and Fig. S4), and were correlated with expression of heart failure
markers. In TAC TRPC 3−/− and TRPC6−/− mice, Nppa and Nppb
expression remained elevated as in the littermate controls, but
were diminished in TRPC3/6 dKO mice exposed to TAC (Fig.
4C). We further examined whether alternative TRPC channels
were regulated in each model before and after TAC. Trpc1 ex-
pression was similar at baseline among the models and changed
only minimally after TAC (Fig. S2).
Assessment of GSK503A in an in Vivo Rat Model of Pressure Overload.
We found that testing the efficacy of either GSK255B or
GSK503A in vivo was impossible in mice, whose extremely fast
metabolism precluded us from obtaining stable effective plasma
concentrations. Testing in rats seemed more plausible, but un-
fortunately, this model proved inadequate as well. In the rat trial,
adult rats underwent ascending aortic constriction (AAC) at 1 wk
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Fig. 2. Effects of TRPC3/6 inhibitor GSK503A on isolated cardiomyocytes.
(A) GSK503A (0.1, 1, 5, and 10 μM) dose-dependently inhibits ET-1–stimu-
lated Rcan-1 luciferase activity in rat neonatal myocytes. #P < 0.05 vs. inactive
control (GSK678A); *P < 0.05 vs. vehicle control. (B) Current-voltage (I-V)
relationship for L-type Ca2+ current (I-VCa-L) in adult mouse cardiomyocytes
treated with GSK503A (10 μM). (C) Gene expression of hypertrophy-related
genes and TRPC channels in adult myocytes exposed to 24 h of ET-1 with or
without coinhibition of TRPC3/6 (GSK503A, 10 μM). n = 6–9 for each con-
dition. Rcan1: *P < 0.03 vs. control, #P = 0.011 vs. ET-1; Nppa: *P < 0.01 vs.
control, #P < 0.03 vs. ET-1; Nppb: *P < 0.001 vs. control, #P < 0.03 vs. ET-1;
Trpc1: *P = 0.06 vs. control; Trpc6: *P = 0.01 vs. control, #P < 0.05 vs. ET-1.
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after initiation of treatment on a maximal dose of GSK503A
(300 mg/kg/wk s.c.) or vehicle control, and were then followed for
7 wk. Total plasma concentration of GSK503A ranged from 200 to
600 ng/mL (0.5–1.5 μM), yielding a protein-free plasma concen-
tration of <0.05 μM. Based on our neonatal rat cardiac ventricular
myocyte assay (Fig. 2A), we expected this level to be in-
sufficient to suppress myocyte hypertrophy, and indeed chronic
treatment did not alter LV mass, fractional shortening, or max-
imal rate of pressure rise, dP/dtmax (Fig. S5A). We did observe
significant fibrosis in vehicle-treated hearts that was not present
with GSK503A treatment (P < 0.02, one-way ANOVA). AAC
increased expression of Trpc3, Trpc6, Rcan1, and gene markers of
pathological hypertrophy (Fig. S5B). Treatment prevented the rise
in TRPC3 and attenuated the rise in TRPC6 (although the latter
remained fourfold above baseline), but did not significantly blunt
the other biomarkers.
Discussion
This study confirms the physiological efficacy and selectivity of
two recently developed TRPC3/TRPC6 antagonists that lack ac-
tivity against voltage-gatedCa2+ andSOCEchannels andbluntGαq
agonist-stimulated hypertrophy in neonatal and adult cardiac myo-
cytes. Although the in vivo experiments in rodents were limited by
inadequate pharmacokinetics, further testing showed that gene
deletion of TRPC3 or TRPC6 alone is not protective against pres-
sure overload in vivo, whereas their combined deletion is protective.
Despite growing evidence supporting its role in pathological
heart disease, therapeutic TRPC3 or TRPC6 inhibition has been
limited by a lack of selective small-molecule inhibitors. BTP2
(N-[4-(3,5-bis(trifluoromethyl)-1H-pyrazol-1–yl)phenyl]-4-methyl-
1,2,3-thiadiazole -5-carboxamide) targets multiple TRPC and
CRAC channels (23), whereas the inositol triphosphate receptor
blocker SKF96365 targets both TRPC and T-type Ca2+ channels
(24). Pyr3, the first reported selective TRPC3 blocker, suppresses
hypertrophic signaling in pressure-overloaded hearts in vivo (16);
however, its impact is relatively mild, with a reported IC50 against
TRPC3 of 0.7 μM (vs. 21 nM for GSK503A), and it is inactive
against TRPC6. Pyr3 also inhibits SOCE due to Orai-1, at con-
centrations close to that for TRPC3 (our data and ref. 19), raising
concerns regarding its selectivity. Selective TRPC6 inhibitors were
recently reported by Urban et al. (25) using the Chembionet li-
brary; however, their IC50 for channel blockade ranged from 3 to
15 μM, and no assessment of hypertrophic modulation was reported.
Given this background, GSK255B and GSK503A (20) repre-
sent major advances in both sensitivity and selectivity against
TRPC3 and TRPC6, with activity in the nM range for cell calcium
entry. InHEK cells, 0.1 μMwas efficient tomarkedly reduceNFAT
activity assayed by a luciferase reporter, and although higher doses
were required in neonatal and adult cardiac myocytes, the se-
lectivity of the blockers persisted, as confirmed both by the ab-
sence of effects in cells lacking both channels and the lack of effect
onLTCC I-Vdependence.Weobserved a small but significant rise
in TRPC1 expression in adult myocytes exposed to ET-1 that was
also suppressed by GSK503A. However, this likely was not an off-
target effect, given that gene TRPC1 expression was unchanged
from baseline in ET-1–treated myocytes lacking only TRPC3/6,
and GSK503A had no further influence in this setting.
An important question relevant to the development of small-
molecule TRPC3 and/or TRPC6 inhibitors is whether blockade
of either channel alone is sufficient to ameliorate cardiac pa-
thology. Both channels are highly homologous and share prop-
erties of G-coupled receptor activation, stimulation of Cn/NFAT,
and up-regulation via an NFAT-consensus sequence in their re-
spective promoters (6). TRPC3 and TRPC6 are known to heter-
otetramerize based on immunoprecipitation and fluorescence
resonance energy transfer studies (26). Genetic models involving
expression of dominant negative proteins (8) may induce a pro-
miscuous effect on the other channel and other TRPC channels;
for instance, TRPC1 also multimerizes with TRPC3 (27). The
present study supports this hypothesis, because neither single gene
deletion model ameliorated hypertrophy/dysfunction with TAC,
whereas the dKO model was more effective.
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Fig. 4. Analyses of morphometric and molecular parameters of hypertro-
phy in mice selectively lacking Trpc3, Trpc6, or both genes and then sub-
jected to TAC. (A) Heart weight/tibia length (at 6–7 wk for dKO and controls
and 3 wk for other models). (B) Myocyte cross-sectional area assessed by
wheat germ agglutinin staining at the terminal study for each model. P
values for one-way ANOVA for each genotype, post hoc test results: *P <
0.05 vs. sham; #P < 0.05 vs. WT-TAC. (C) Response of hypertrophy-related
fetal genes (Nppa and Nppb) for each model. *P < 0.05 vs. sham; #P < 0.05 vs.
WT-TAC; §P = 0.07 vs. WT-TAC.
1554 | www.pnas.org/cgi/doi/10.1073/pnas.1308963111 Seo et al.
From the perspective of drug development, however, it remains
possible that agents targeting one channel subtype will similarly af-
fect the other subtype in a heterotetramer. This could explain the
efficacy of Pyr3 despite its blockage of only TRPC3.Whether this or
a dual-channel blocker is the optimal strategy remains unclear be-
cause of the uncertain stoichiometry of these channel subunits in
vivo, particularly when one species is more highly up-regulated, as
often the case forTRPC6. In this regard, our present in vivo rat study
found that even with suppression of TRPC3 back to resting levels,
persistent marked elevation of TRPC6 despite GSK503A adminis-
tration correlatedwith the lack of an alteredhypertrophyphenotype.
The magnitude of Ca2+ entry via TRPC3 or TRPC6 is consid-
ered quite small relative to that from voltage-gated channels,
raising the suspicion that some interaction between these species is
essential for maladaptive hypertrophy signaling (28). Others have
shown that TRPC6-stimulatedNFATactivity is not inhibited by the
LTCCblocker nifedipine, however (9). Klaiber et al. (29) reported
that Ca2+ entry in response to Ang II was depressed in myocytes
lacking both TRPC3 and TRPC6, whereas entry in response to
isoproterenol was unchanged despite direct engagement of LTCC
channels by the latter. Our present data further support separation
of these calcium pools, because the TRPC3/6 antagonists exert no
demonstrable inhibitory activity against LTCC, yet suppress hy-
pertrophy signaling only in cells expressing both TRPC species.
Our study has several limitations. The gene KO models were
global, so the relative contribution of myocytes versus fibroblasts
or smooth muscle cells cannot be discerned. Previous myocyte-
targeted dominant negative approaches (8) and our present in
vitro data support relevance in myocytes, however. Because
small-molecule inhibitors likely influence multiple cell types as
well, these global KO data are relevant. Moreover, the models
displayed a less-marked hypertrophic response even in littermate
controls, as seen in pure C57BL/6J mice, which may explain the
lack of rise in TRPC3 expression and the more modest rise in
TRPC6 compared with some previous data (9, 16). Finally, de-
spite the considerable effort in rats, translation of the new
TRPC3/6 antagonists in vivo must await further pharmacokinetic
modifications so that adequate plasma concentrations can be
achieved. Nonetheless, the compounds presented here represent
a class that obviates many of the ambiguities associated with
existing inhibitors and will enhance basic studies of these chan-
nels and their role to a growing range of disease conditions.
Materials and Methods
Pharmaceuticals. Selective dual TRPC3/TRPC6 small-molecule inhibitors
GSK2332255B (GSK255B, example 17) and GSK2833503A (GSK503A, example
19) and corresponding inactive controls [GSK2346383A (GSK383A) and
GSK2402678A (GSK678A)] were studied (20). GSK255B has an IC50 = 5 nM
for TRPC3 and 4 nM for TRPC6, whereas GSK503A has an IC50 = 21 nM for
TRPC3 and 3 nM for TRPC6, as determined by patch- clamping in HEK
cells expressing both channels (SI Materials and Methods). Both inactive
controls had an IC50 > 25 μM for both TRPC3 and TRPC6. These compounds
were also tested against voltage-gated calcium channels (CaV1.2, IC50 = 0 μM),
hERG (IC50 > 50 μM), and NaV1.5 (IC50 > 3.3 μM). All compounds were first
dissolved in 100% DMSO and then diluted 1:1,000 in culture media. Ang II and
ET-1 (Sigma-Aldrich) were diluted in nuclease-free double-distilled H2O. These
studies initially used GSK255B, but once GSK503Awas identified and appeared
to be slightly more potent with potentially more favorable in vivo pharma-
cokinetics, this compound was substituted. Both compounds were tested in
the same neonatal myocyte assay.
Plasmids. We obtained pcDNA3-human TRPC6-YFP from Craig Montell
(Molecular, Cellular, and Developmental Biology, University of California
Santa Barbara, Santa Barbara, CA) (30), pcDNA3-human TRPC3 from Jeffery
Molkentin (Howard Hughes Medical Institute, Cincinnati Childrens Hospital
Medical Center, Cincinnati), and pcDNA3-mouse angiotensin II type 1 re-
ceptor (AT1R) from Akiyoshi Fukamizu (Life Science Center, Tsukuba
Advanced Research Alliance, University of Tsukuba, Tsukuba, Ibaraki, Japan)
(31). pGL4.30-NFAT-RE firefly luciferase vector (NFAT-luc) with an NFAT re-
sponse element driving the transcription of firefly luciferase, pGL4.75-CMV
Renilla luciferase vector (CMV-Rluc), and pGL4.74-TK (thymidine kinase)
Renilla luciferase (TK-Rluc) vector were purchased from Promega. A TRPC6-
phosphomimetic mutant (S322E and T70E) was generated by PCR-based site
mutagenesis (QuikChange; Stratagene) using pcDNA3-human TRPC6-YFP as
the template, as described previously (9). pcDNA3 served as an empty vector
control for all transfection protocols. pGL3-RCAN1-firefly luciferase vector, in
which RCAN1 intron 3 containing 15 NFAT-binding sites was inserted upstream
of the luciferase reporter gene, was generated by Beverly Rothermel and
provided by Eric Olson (Department of Molecular Biology, University of Texas
Southwestern, Dallas) (32).
TRPC3/6 Gene Deletion Mice. TRPC3 KO (TRPC3−/−) and TRPC6 KO (TRPC6−/−)
mice were previously generated as described (33, 34). Each individual KO
mouse model was backcrossed for at least five generations into a C57BL/6J
background, and their cross yielded the combined TRPC3/TRPC6 dKO (TRPC3/
6−/−) mouse. Age-matched KO and WT littermate controls were used for all
studies. All experiments were conducted in accordance with National Insti-
tutes of Health Guidelines for the Care and Use of Animals and were
reviewed by the Institutional Animal Care and Use Committee at the in-
stitution where the work was performed.
HEK293T Cell Experiments. HEK293T cells were cultured to 50% confluence
and then transfected with plasmid containing AT1R, NFAT-luc, and CMV-luc
(internal control) as described previously (9). HEK293T cells do not express
TRPC6 and express TRPC3 only at very low levels. For our studies, cells were
transfected with WT-TRPC3, WT-TRPC6, or empty vector pcDNA to aug-
ment signaling to channel stimulation by a Gαq receptor-coupled agonist.
After transfection, cultures were maintained in serum-free medium for
24 h. Cultures were then treated with Ang II with or without a TRPC3/6
inhibitor, vehicle, or inactive control for 4 h, then harvested using
the Dual-Luciferase Reporter Assay System (Promega), following the
manufacturer’s protocol.
Isolated Ventricular Myocyte Studies. Neonatal rat cardiac ventricular myo-
cytes were isolated from 1- to 3-d-old Sprague–Dawley rats as described
previously (35). Cultures were maintained in 10% FBS containing culture
medium for 36 h after isolation. Cells were transfected with RCAN1-luc and
TK-luc (as an internal control) using Xfect transfection reagent (Clontech)
according to the manufacturer’s protocol. After transfection, cells were
maintained in serum-free medium for 24 h, then exposed to ET-1 with or
without TRPC3/6 inhibitor, vehicle, or inactive control for 24 h. Cells were
harvested with cell lysis buffer (Promega), and luciferase activity was mea-
sured with a GloMax 96 microplate luminometer (Promega) using the Dual-
Luciferase Report Assay System (Promega).
For functional studies of cytosolic Ca2+, cells were loaded with 1 μM Fura-2/
AM (Molecular Probes) for 20 min at room temperature in serum-free medium
or in Tyrode’s solution containing 10 mM Hepes, 140 mM NaCl, 5 mM KCl, 1
mM MgCl2, 1 mM CaCl2, and 5.5 mM glucose (pH 7.4). After incubation, cells
were bathed in Ca2+-free Tyrode’s solution and then incubated with 1 μM
thapsigargin and 20 μM PE. The solution was then switched to 2 mM Ca2+-
Tyrode’s solution with thapsigargin to assess Ca2+ influx in the presence of
PE with or without the TRPC3/6 inhibitor (GSK255B, 10 μM). Cytosolic Ca2+
was monitored with an Olympus IX81 inverted fluorescence microscope and
Slidebook software, using excitation wavelengths of 340 and 380 nm to
detect Fura-2/AM fluorescence emission at 510 nm.
Studies were also performed in primary ventricular myocytes isolated from
adult mice from dKO and littermate controls following the methodology of
O’Connell et al. with minor modifications (9, 36). To enhance expression of
the channels, which is low under normal conditions, hearts were subjected
to 1 wk of pressure overload (i.e., TAC) (9). After euthanasia, the mouse
heart was promptly removed from the chest, and the aorta was retro-
perfused at 37 °C for 3 min with a Ca2+-free bicarbonate-based isolation
buffer. Enzymatic digestion was initiated by adding 0.9 mg/mL collagenase
type 2 (Worthington) and 0.05 mg/mL protease type XIV (Sigma-Aldrich) to
the perfusion solution for 6–7 min. Dispersed myocytes were incubated in
buffer with increasing concentrations of Ca2+, finally achieving a concen-
tration of 1.2 mM Ca2+ as in MEM culture media (Sigma-Aldrich) containing
insulin-transferrin-selenium and penicillin-streptomycin (Gibco).
Cells were seeded at 25,000 rod-shaped myocytes/mL on six-well laminin-
coated plates. The myosin ATPase inhibitor 2,3-butanedione monoxime
(10 mM) was added to the perfusion buffer and culture medium to provide
myocyte cytoprotection. At 1 h after incubation at 37 °C in 5% CO2, the culture
medium was replaced to remove unattached cells, and cells were stimulated
with ET-1 (0.1 μM) with or without concomitant TRPC3/6 blockade (GSK503A,
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10 μM). Cells were harvested 24 h later and analyzed by quantitative PCR
(qPCR) to assess expression of hypertrophic signaling genes.
In Vivo Pressure Overload Studies. TAC was performed in 10- to 16-wk-old
TRPC3 KO and TRPC6 KO and dKOmice and corresponding littermate controls
as described previously (9). Sham-operated mice underwent the same sur-
gery without aortic constriction. Conscious mice were assessed by serial
echocardiography (Acuson Sequoia C256, 13-MHz transducer; Siemens), and
chamber dimensions and LV mass were measured (heart rate >600 min−1).
The analysis was blinded to genotype. All protocols were approved by The
Johns Hopkins University Animal Care and Use Committee.
For rat studies, Wistar rat weanlings (∼50 g, 3 wk) were pretreated
with vehicle (corn oil 10 mL/kg once weekly s.c.) or GSK503A (300 mg/kg)
for 7 d. The rats were then anesthetized with isoflurane (Abbot Scandinavia)
and ventilated (UB 7025; Hugo Sachs Elektronik/Harvard Apparatus). The
ascending aorta was accessed and constricted as described previously
(37). Sham animals underwent the same procedure without banding. Drug
plasma concentrations were measured at 1, 4, and 8 wk after the start of
treatment. All experiments were performed in accordance with the Guide
for the Care and Use of Laboratory Animals published by the National
Institutes of Health (Publication 85-23, revised 1985) and were approved by
the Danish Animal Experiments Inspectorate (2012-15-2934-00071).
Rat echocardiography was performed by a trained and blinded operator
using a Vivid 7 echocardiography system (GE Healthcare) with an 11-MHz
transducer on lightly anesthetized rats. LV pressures were assessed trans-
apically using a 1.4F pressure catheter (Millar Instruments).
Patch-Clamp Studies, Histology, and Gene Expression by qPCR. Detailed in-
formation on patch-clamp studies, histology, and qPCR assays is provided in SI
Materials and Methods.
Statistical Analysis. Statistical analyses were performed with one-way or two-
way ANOVA for normally distributed data with equal variance among groups
and with the Kruskal–Wallis test for other data. Post hoc analysis was
performed using the Tukey–Kramer or Mann–Whitney U test, as appropri-
ate, along with the Fisher least squares estimate test. Analyses were per-
formed using SigmaStat version 13 and Systat version 10 software.
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SI Materials and Methods
Patch-Clamp Studies. Intracellular AlF4
− was used to activate re-
combinant transient receptor potential canonical channel type 3
or type 6 (rTRPC3, rTRPC6) current in transduced HEK293
cells (1). HEK293 cells were cultured to 50–70% confluence and
transduced with BacMam virus expressing the rTRPC3 or
rTRPC6 gene (8–12% vol/vol) for 48 h. The transduced cells
were trypsinized and stored in Dulbecco’s Modified Eagle Me-
dium DMEM/F-12 + 10% FBS at room temperature for patch-
clamp experiments within 5 h. Cells were perfused with an ex-
ternal solution (∼3 mL/min) at room temperature (22 °C). The
electrodes, made from glass capillary tubes, had a resistance of
2–4 MΩ when filled with internal solution containing AlF4− [110
mM CsF, 20 mM CsCl, 10 mM Hepes, 10 mM EGTA, and 10
mM NaF; pH 7.2), plus 15 μM AlCl3]. An Axopatch 200B am-
plifier and pCLAMP 8 software (Molecular Devices) were used
for data acquisition and analysis.
The seal between the cell membrane and electrode was created
in the external solution containing 140 mM NaCl, 4 mM KCl,
1 mM MgCl2, 0.2 mM CaCl2, 10 mM glucose, and 10 mM Hepes
(pH 7.4). Once the whole-cell configuration was established, the
external solution was switched to the EGTA-containing solution
(140 mMNaCl, 4 mMKCl, 1 mMMgCl2, 2 mMNa4EGTA, 10 mM
glucose, and 10 mM Hepes; pH 7.4), to minimize desensitization
of the TRPC current. Cell membrane capacitance was canceled
electronically, and the series resistance was compensated by
approximately 70%.
To record TRPC current, a ramp voltage protocol was applied
every 10 s for the suration of the experiment. The ramp protocol
stepped from a holding voltage of −60 mV to −80 mV for 40 ms
and then depolarized to +80 mV in 400 ms, then stepped back to
holding voltage after 40 ms at +80 mV. rTRPC3 or rTRPC6
current gradually increased as the cell was dialyzed with the in-
ternal solution containing AlF4
−. For a large portion of cells, we
were able to record a relatively stable rTRPC3 or rTRPC6 current.
Once the control current stabilized, the recording chamber was
perfused with the EGTA external solution containing a testing
compound. At each drug concentration, 2∼3 min was allowed for
the drug effect to reach steady state. At the end of the experiment,
a positive control compound (GSK417651A) was applied to the
cell to completely block the rTRPC3 or rTRPC6 current. Zero
current (background) level was set at the end of GSK417651A
perfusion. The rTRPC3 or rTRPC6 current amplitude was mea-
sured as the average current at +80 mV.
We plotted the time course of current for the whole experi-
ment: % inhibition = 100 × (1 − ID/IC), where ID is the current
amplitude measured at the end of a particular drug concentra-
tion perfusion and IC is the control current amplitude measured
before drug application. We calculated the average % inhibition
at each drug concentration first. The averaged data were fit using
the four-parameter logistic equation model and Origin 7.0 soft-
ware to calculate IC50.
We measured L-type calcium channel current-voltage rela-
tionships by whole-cell patch-clamp studies as described pre-
viously (2). In brief, myocytes were loaded into a heated chamber
(37 °C) on the stage of a fluorescence microscope (Nikon Eclipse
TE300) and superfused with Cs-Tyrode’s solution containing 130
mM NaCl, 5 mM CsCl, 2 mM MgCl2, 10 mM Na-Hepes, 2 mM
CaCl2, and 10 mM glucose (pH 7.4). Myocytes were whole-cell
patch-clamped with 2–4 MΩ pipettes and equilibrated with
a pipette solution containing 110 mM CsCl, 0.5 mM MgCl2, 10
mM Hepes, 5 mM Mg-ATP, 5 mM 1,2-bis(o-aminophenoxy)
ethane-N,N,N′,N′-tetraacetic acid, and 20 mM tetraethylammo-
nium (pH 7.25). Then 10 μM GSK503A was added to the Cs-
Tyrode’s solution. After achievement of whole-cell conformation,
cells were voltage-clamped at a holding potential of −80 mV.
L-type Ca2+ current (ICa-L) was recorded by applying a depo-
larizing pulse of 0 mV or a series of pulses ranging from −40
to +50 mV in 10-mV steps for 300 ms after a 200-ms prepulse
to −40 mV.
CRAC Activity Assay.Calcium release activated channel activity was
determined using a Fluo4 fluorescence assay in Jurkat E6-1 cells
stimulated with CaCl in the presence of thapsigargin (500 nM) as
described previously (1).
Histology. For wheat germ agglutinin staining of mouse heart
sections, myocardium was fixed with 4% paraformaldehyde,
paraffin-embedded, sectioned into 4-μm slices, deparaffinized,
rehydrated, and subjected to citrate-based head-mediated anti-
gen retrieval. Slides were incubated with 5 μg/mL Alexa Fluor
647-conjugated wheat germ agglutinin (Invitrogen) overnight at
4 °C and mounted using Prolong Gold mounting medium (In-
vitrogen). Image acquisition was performed on an EVOS epi-
fluorescence microscope (Life Technologies). Myocyte cross-
sectional area was measured blinded to the treatment group and
genotype using an automated algorithm with Image J 1.47i soft-
ware, analyzing 1,040 ± 70 cells from 6–16 areas per mouse heart.
Rat left ventricles were formalin-fixed, paraffin-embedded, and
sectioned following routine procedures, then stained with Sirius
red to visualize fibrosis in polarized light. Digital color images
of the left ventricle (ColorViewII; Soft Imaging System) were
captured and analyzed using ImageJ software after conversion to
an 8-bit grayscale and manual thresholding. The mean area of fi-
brosis was calculated by a blinded investigator as the average per-
centage of images without large vessels, epicardium, or pericardium.
Gene Expression by PCR.Quantitative PCR was used to assess fetal
and hypertrophic gene expression and TRPC1, TRPC3, or TRPC6
expression in cells and myocardial tissue. RNA was extracted with
TRIzol (Invitrogen), and cDNA was synthesized by TaqMan re-
verse-transcription reagents following the manufacturer’s recom-
mended protocol (Applied Biosystems). Quantitative real-time
PCR was performed with the 7900HT Sequence Detection Sys-
tem (Applied Biosystems) with sample duplicates. TaqMan pri-
mers and probes for rat and mouse were obtained from Applied
Biosystems. Gene expression was calculated using the ΔΔCt
method, and normalized to GAPDH expression.
1. Kraft R (2007) The Na+/Ca2+ exchange inhibitor KB-R7943 potently blocks TRPC
channels. Biochem Biophys Res Commun 361(1):230–236.
2. Ganesan AN, Maack C, Johns DC, Sidor A, O’Rourke B (2006) Beta-adrenergic
stimulation of L-type Ca2+ channels in cardiac myocytes requires the distal carboxyl
terminus of alpha1C but not serine 1928. Circ Res 98(2):e11–e18.
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Fig. S1. Rcan1 luciferase activity in neonatal rat cardiomyocytes stimulated with 0.1 μM endothelin-1 (ET-1) and treated with GSK255B or inactive control
(GSK383A). †P < 0.05 vs. vehicle control; *P < 0.05 vs. vehicle + ET-1; #P < 0.05 vs. inactive control (GSK383A).
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Fig. S2. Gene expression of Trpc1, Trpc3, and Trpc6 at rest and after TAC for WT and TRPC3- or TRPC6-selective or double KO genotype. *P < 0.05 vs. sham;
#P < 0.001 vs. sham; †P = 0.1 vs. sham. The numbers of mice employed for each data point is displayed on the graphs.
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Fig. S3. Echocardiographic analyses of left ventricular mass and fractional shortening in TRPC3/6 double KO mice subjected to 6–7 wk of TAC. P values denote
(group) × (time) interaction based on ANCOVA; symbols identify the interaction term for pairwise covariance analysis versus sham control (*P < 0.001) or WT-
TAC (#P < 0.001; {P < 0.002). Sham control data combine the littermate and KO groups, because there was no significant difference between them. Data for
baseline (BL) and 1 and 3 weeks after TAC are as shown in Fig. 3C, with the addition of the 6–7 week time point shown here.
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Fig. S4. Representative images of wheat germ agglutinin-stained left ventricular myocardium sections from mice exposed to pressure overload (n = 5–6 per
group).
0.0
5.0
10.0
Trpc6/gapdh
#
0.0
1.0
2.0
Trpc3/gapdh
#
0.0
10.0
20.0
30.0
40.0
Nppa/gapdh
* *
0.0
2.0
4.0
6.0
Rcan1/gapdh
0.0
4.0
8.0
Myh7/gapdh
A
B
0.0
1.0
2.0
(%
)
Fibrosis
0
20
40
60
(%
)
Fractional Shortening
* *
0
5,000
10,000
(m
m
H
g/
s)
dP/dtmax
* *
0
20
40
(m
g/
m
m
)
LV mass / TL
* *
0.0
5.0
10.0
Nppb/gapdh
*
*
sham TAC +veh TAC +GSK503A
*
<0.005 <0.002 
<0.0001 <0.02 
<0.01 * <0.001 <0.001
<0.01 <0.001 <0.001
Fig. S5. (A) Chronic treatment of rats with GSK503A had no effect on functional parameters (fractional shortening, maximal rate of pressure rise dP/dtmax) or
interstitial fibrosis. The left ventricular mass normalized to tibia length (TL) was increased in vehicle- and GSK503A-treated TAC animals. (B) Trpc3 and Trpc6
gene expression increased after aortic banding in rats and was reduced by GSK503A treatment. Molecular heart failure markers (Nppa, Nppb, and Myh7) and
Rcan1 expression were increased in banded hearts, but were not affected by GSK503A treatment. *P < 0.05 vs. sham; #P < 0.05 vs. vehicle; †P < 0.01 vs. sham.
n = 8–10 for molecular studies; n = 10–14 for functional studies and fibrosis.
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